绿叶制药(02186.HK) 公布,若干附属与江苏恩华药业股份附属恩华和信签署合作协议,授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此,恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞,均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻
Source Link绿叶制药(02186.HK) 公布,若干附属与江苏恩华药业股份附属恩华和信签署合作协议,授予恩华和信三款抗精神病药长效针剂产品在中国的独家商业化权利。据此,恩华和信将向集团一次性支付2,000万美元授权费。涉及三款产品包括瑞可妥、瑞百莱和美比瑞,均适用于精神分裂症的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-12-24 12:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.